Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  Adverse effect
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Reversible anorgasmia with topiramate therapy for migraine prophylaxis

100%
Kilbas S., Kilbas A., Uzar E.
Open Medicine
|
2010
|
vol. 5
|
issue 6
691-692
EN
Topiramate is an effective drug for the prevention of migraine headaches. On occasion, topiramate can be associated with a dose-related anorgasmia. Presented here is an adult case of reversible anorgasmia induced by and possibly attributable to topiramate therapy. Physicians need to be aware of the potential for topiramate to dose related reversible anorgasmia, and should inquire about sexual symptoms of patients.
2
Content available remote

Adverse reaction of a combined treatment for unresectable liver cancer

88%
Ren J., Jiang T., Peng R.
Open Medicine
|
2014
|
vol. 9
|
issue 2
272-278
EN
To investigate the adverse reactions of transcatheter arterial chemoembolization (TACE) combined with trastuzumab in the treatment of unresectable live cancer, 85 unresectable liver cancer patients were treated with 35 mg epirubicin, with lipiodol and gelatin sponge granule as the embolic agent, and trastuzumab (4mg/kg) was administered intravenously. All the adverse reactions were investigated by blood routine examination and the checking of liver, renal and thyroid functions on the postoperative 2nd and 30th day. No patients died of direct medication. The main adverse reactions included haematological toxicity, liver function lesion and postoperative syndromes such as nausea, vomiting, fever and liver area aching. Two days after the treatment, the amount of the serum total bilirubin (TB) and white blood cell (WBC) increased dramatically, while platelet (PLT) changed a little, and creatinine (Cr) and blood urea nitrogen (BUN) did not change at all. Thirty days after the treatment, blood routine, liver and renal functions were examined, demonstrating that the liver function remained unchanged, PLT decreased apparently, WBC was lower, and Cr and BUN changed slightly compared to those before the treatment. The combined treatment is safe for unresectable liver cancer and thus can be used as a routine intervention method.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.